Synta Pharmaceuticals Corp.  

(Public, NASDAQ:SNTA)   Watch this stock  
Find more results for SNTA
-0.03 (-0.79%)
Real-time:   1:31PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.35 - 4.49
52 week 3.70 - 7.85
Open 4.48
Vol / Avg. 642,430.00/1.82M
Mkt cap 395.42M
P/E     -
Div/yield     -
EPS -1.25
Shares 90.38M
Beta 2.56
Inst. own 24%
Jun 25, 2014
Synta Pharmaceuticals Corp at JMP Securities Healthcare Conference
Jun 12, 2014
Synta Pharmaceuticals Corp. Annual Shareholder Meeting
Jun 5, 2014
Synta Pharmaceuticals Corp. at Jefferies Global Healthcare Conference - Webcast
May 8, 2014
Q1 2014 Synta Pharmaceuticals Corp. Earnings Conference Call - Webcast
May 8, 2014
Q1 2014 Synta Pharmaceuticals Corp. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -106.53% -91.00%
Return on average equity -216.43% -145.29%
Employees 134 -
CDP Score - -


United States - Map
+1-781-2748200 (Phone)
+1-781-2748228 (Fax)

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Synta Pharmaceuticals Corp. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing small molecule drugs to severe the medical conditions of the patients with cancer and inflammatory diseases. As of December 31, 2011, it had two drug candidates in clinical trials for treating multiple types of cancer and several drug candidates in the preclinical-stage of development. Its drug candidates are discovered and developed internally, using its chemical compound library and integrated discovery engine. During the year ended December 31, 2011, it initiated a Phase 2b/3 clinical trial (GALAXY) of ganetespib in combination with docetaxel in non-small cell lung cancer (NSCLC). As of December 31, 2011, it had two clinical-stage programs and one preclinical-stage program in oncology. In 2011, in addition to focusing on ganetespib program, the Company also focused on its elesclomol and calcium release activated calcium modulator (CRAC) programs.

Officers and directors

Keith R. Gollust Independent Executive Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
Keith S. Ehrlich CPA Chief Financial Officer, Vice President - Finance and Administration
Age: 63
Bio & Compensation  - Reuters
Arthur J. McMahon Senior Vice President - People Operations
Age: 68
Bio & Compensation  - Reuters
Vojo Vukovic M.D., Ph.D. Senior Vice President, Chief Medical Officer
Age: 47
Bio & Compensation  - Reuters
Wendy E. Rieder Esq. Vice President - Intellectual Property and Legal Affairs, General Counsel
Age: 46
Bio & Compensation  - Reuters
Paul A. Friedman M.D. Director
Age: 71
Bio & Compensation  - Reuters
Bruce S. Kovner Independent Director
Age: 69
Bio & Compensation  - Reuters
Donald W. Kufe M.D. Independent Director
Age: 69
Bio & Compensation  - Reuters
William S. Reardon CPA Independent Director
Age: 67
Bio & Compensation  - Reuters
Robert N. Wilson Independent Director
Age: 73
Bio & Compensation  - Reuters